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ABSTRACT
Mental health nursing is a complex and radically changing discipline that must
continuously adapt to evidence based practices, including the use of alternative options
for the treatment of mental illness. There has recently been increased research into the
use of hallucinogenic and sedative drugs for the treatment of mental illness.
Hallucinogenic and sedative drugs were examined as potential treatment options for a
variety of mental illnesses in the 1960s, although these trials were ceased by the
government due to human safety concerns. The United States Food and Drug
Administration (FDA) has recently approved trials to study the use of hallucinogenic
drugs to treat mental illness, and sedative drugs, such as ketamine are currently FDA
approved to treat major depressive disorder. This presentation will provide an overview
of the literature regarding the history of hallucinogenic and sedative drug trials, as well as
current research on the use of these drugs to treat mental illness. The potential impact that
these drugs could have on mental health treatment will be discussed, as well as the
evolution of the mental health nursing role, especially as it pertains to these innovative
treatment options.
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HISTORY OF MENTAL HEALTH CARE, STIGMAS, AND PSYCHIATRIC
NURSING
Throughout the history of society, mental illnesses have been stigmatized and, in
the past, may not have been emphasized as important to address when providing
healthcare to individuals. In recent years, more of an emphasis has been placed on the
treatment of mental illness and its importance in overall wellness; however, seeking
mental health treatment may still be considered taboo in various cultures across the
world. Individuals may fear being outcast in society due to their mental illness, and
therefore, do not seek out the necessary treatment to live a healthy life.
Psychiatric nurses play an important role in providing care for individuals with
mental illness, although this area of nursing can be under-appreciated. Halter (2002)
explores the lack of discussion about the stigmas that plague the profession of mental
health nursing and discusses the effects of these stigmas on nursing students. Halter
(2002) found that some students have reported the idea of psychiatric nursing as being a
backup option, or that they had been warned by their family to not enter into this field of
nursing. Media sources have overdramatized the role of mental health nursing and have
contributed to some of the stigma in this area of nursing (Halter, 2002). These stereotypes
of what are expected in a psychiatric unit or hospital are usually thought of as something
out of a movie, such as One Flew Over Cuckoo’s Nest, Psycho, or the negative images of
these settings from TV shows and other media outlet influences, which are readily
available to the general public (Anderson, 2003). Great strides have been necessary in
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recent years to reduce the stigmas and negative stereotypes of what mental healthcare and
psychiatric nursing consists of in the eyes of the public. Psychiatric nurses can play a
significant role in changing the idea that receiving mental healthcare is embarrassing or
will cause societal disapproval.
Stigmatism in the field of psychiatric nursing is not only seen with the general
public, but also among other health care professionals. Halter (2002) described how some
healthcare professionals assume nurses go into the psychiatric field because of their own
psychological flaws or trauma from their childhood. These assumptions only fuel the
stereotypes that flood this profession. Halter (2002) stated, “Psychiatric nursing’s silence
on negative perceptions, and perhaps stigmatization by nursing students, colleagues, and
the general public, is both noteworthy and alarming” (p. 25). It is important for not only
the public, but also the health care community to credit the psychiatric profession with
the recognition and value it deserves.
Psychiatric nursing care is much different than the care that is delivered by other
types of nurses, such as medical surgical nurses, but is also an extremely important skill
for nurses working in all settings. In all parts of the hospital, or any medical setting, you
are guaranteed to run into a mental health situation. Many patients have mental health
needs; thus, it is expected that all nurses will utilize psychiatric nursing skills during their
career. As a psychiatric nurse, you still have the life of your patients in your hands;
however, it is vastly different than making sure your patient stays alive from an illness
that you can visibly see, such as hypertension or diabetes. The responsibility of the entire
floor falls to the nursing staff as the patients are a danger to themselves or others or are
unable to care for themselves. Psychiatric nurses then have the responsibilities of not only
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their patients, but also the unit as a whole, which can obviously be extremely difficult
(Thomson et al., 2019). Psychiatric nurses are also in unique a position to build rapport
and trust with their patients and can assist with creating opportunities to help these
patients with considering various modes of treatment options during their time of need
(Denis-Lalonde & Estefan, 2020).
A holistic approach must be utilized in psychiatric nursing, which allows for a
more individualized approach to each patient’s needs. This holistic approach includes
using the best evidence-based practice and may include the use of alternative drug
treatments. Some of the drugs traditionally used to treat mental illness may not be as
effective for patients as once thought (Wong, 2017). In recent years, the use of
psychedelic and sedative drugs has been researched as a viable option for the treatment of
a variety of mental illnesses, and some states have even legalized the use of these drugs.
For instance, in 2020 Oregon became the first state in the nation to legalize the use of
psilocybin, the hallucinogenic ingredient in mushrooms, as a treatment option for posttraumatic stress disorder (PTSD), depression, and anxiety (Foden-Vencil, 2020).
Psychiatric nurses may be in a prime position to play a role in the oversight of
psychedelic drug use for the treatment of mental illness (Denis-Lalonde & Estefan,
2020).
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THE HISTORY OF THE USE OF PSYCHEDELIC AND SEDATIVE DRUG
TREATMENTS FROM THE 1950’s TO THE 1960’s
The use of psychedelic drug treatment is not new to the medical field. In the past,
clinical trials examined the use of hallucinogenic drugs for a variety of medical
treatments; however, due to safety and ethical concerns these trials were halted. With
changes in clinical research trials, the use of hallucinogenic drugs has again become a
viable treatment option, especially for individuals with mental illness; however, it is
important to look back at the history of psychedelic drug use before exploring the current
use of these alternative treatment options.
According to Wong (2017), “The idea that psychedelic drugs might be used to
treat mental illness emerged in the 1950s, a decade or so after Swiss chemist Albert
Hofmann first described his experiences of taking LSD” (para 4.) In the past, the drug
LSD was used in a few unorthodox clinical trials. Most notably, in the 1960s, Doctors
Timothy Leary and Richard Alpert, conducted the Harvard Psilocybin Project, where
they used Psilocybin as a way to further understand human psychology as it relates to the
environment and how psychedelics affect the human brain (Harvard University,
Department of Psychology, 2021). The project was shut down by Harvard and both
professors were banished from academia when it was discovered that their study did not
follow the code of ethics. Leary and Alpert were said to have given the drug to
undergraduate and graduate students without their consent, all while they themselves
were using the hallucinogen (Harvard University, Department of Psychology, 2021).
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Dr. Sidney Cohen made waves in the 1960s discussing the use of LSD as a
treatment for alcoholism and as a method for enhancing creativity (Novak, 1997).
Initially, Dr. Cohen stated that LSD appeared to be safe for medical use in a supervised
setting; however, his opinion changed in 1962 when he stated that this drug was
dangerous. The abuse of LSD led the government to crackdown on LSD regulation.
Before he deemed LSD dangerous, Dr. Cohen conducted three different LSD clinical
trials to attempt to understand the drug’s effect on the human psyche. Initially Dr. Cohen
believed that LSD had the possibility to treat some mental disorders. He mainly focused
on treating minor personality disorders in the late 1950s. During these clinical trials, Dr.
Cohen evaluated his patients six months after the therapy by the terms of their ability to
find a job, sustain a relationship, or remain abstinent from alcohol, and his findings
indicated a 73% improvement rate in these patients based on his criteria (Novak, 1997).
Although Dr. Cohen’s research showed promise for the future use of psychedelic drugs to
treat mental illness, LSD was being abused at the time, which eliminated any idea that it
could be a treatment option.
In the 1960s, a project funded by NASA attempted to examine an unusual way to
communicate with dolphins (Burnett, 2010). Dr. John C. Lilly injected himself and a
dolphin named Peter with LSD in search of a new way to communicate. As would be
expected, when NASA got word of what was happening the study was immediately shut
down. It is important to note that this study did not go without its benefits. As a result of
Dr. Lilly’s work, the idea that dolphins are an intelligent species was discovered and the
Marine Life Protection Act was enacted (Burnett, 2010).
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Another notable psychedelic drug research trial was conducted in 1957 by a
psychiatrist named Dr. Humphry Osmond (Denis-Lalonde & Estefan, 2020). Dr. Osmond
researched LSD and believed this drug was showing promise as a possible treatment for
mental illness. Osmond tested the use of LSD as a way to possibly understand
schizophrenia. He then shifted to examining LSD as a therapeutic option for alcoholism,
which after one year demonstrated a 40-45% improvement rate in participants being
studied; however, not long after these findings were discovered support for this type of
research was withdrawn (Denis-Lalonde & Estefan, 2020).
After the cessation of the above mentioned experiments, the use of LSD, or any
other form of psychedelics in the scientific realm became untouchable. In 1970, not long
after these experiments, President Nixon passed the Controlled Substance Act, which
made these once legal drugs, illegal (Philips, 2019). The idea of the therapeutic use of
hallucinogenic drugs had become taboo and was no longer considered as viable treatment
option for mental illnesses.
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CURRENT RESEARCH AND USE OF PSYCHEDELIC AND SEDATIVE DRUG
TREATMENTS
The use of hallucinogenic and sedative drugs has recently been reexamined as an
option for the treatment of mental illness, since some common drug treatment options
have been discovered as not being as effective as researchers once thought (Wong, 2017).
For example, selective serotonin reuptake inhibitors (SSRI’s), which are drugs commonly
used to treat depression, have only been found to be effective in 1 out of 5 people, and in
addition, may come with undesired side effects (Wong, 2017). PTSD is a mental illness
that can be difficult to treat and may not respond well to traditional psychiatric
medications, and because of this psychedelics are again being researched as a potential
treatment option for this disorder. For instance, MDMA (Ecstasy), which works by
flooding the brain with serotonin, has recently been used in clinical trials for the
treatment of individuals with PTSD. In these trials, MDMA allowed for 67% of
participants to no longer experience symptoms of PTSD. These findings have led to
increased studies into the use of hallucinogenic and sedative drug treatments for mental
illnesses in recent years (Wong, 2017).
The opportunity for previously illegal drugs to possibly become a treatment
option is controversial and highly stigmatized. The lack of success in the past with
hallucinogenic and sedative drug trials has contributed to negative views of these drugs
as a credible treatment option. The concern for public safety as these drugs entered the
black market made way for greater drug regulations and government intervention. Since
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the role that these drugs play in the treatment of mental illness now have become less
stigmatized, more research is being conducted on their potential use. Institutions, such as
Imperial, John Hopkins, Berkley, University of California, and Icahn School of Medicine
have all opened centers devoted to learning more about the treatment options of
psychedelic drugs (Tullis, 2021).
Tullis (2021) states, “psychedelic-assisted psychotherapy could provide needed
options for debilitating mental-health disorders including PTSD, major depressive
disorder, alcohol use disorder, anorexia nervosa and more that kill thousands every year
in the United States, and cost billions worldwide in lost productivity” (p. 507). The proof
behind this bold statement lies within several small studies that have been safely
conducted with psychedelics, which have indicated a positive impact on the outcomes of
mental illnesses. With this new information coming to light in safe clinical trials, there is
greater possibility that some of these previously illegal drugs could now become a new
treatment option for some difficult to treat mental health disorders. Since these alternative
drug treatments have just recently been reexamined in research, many clinical trials have
just ended and the results should be released soon, which will then be given to regulators
to decide if this could be a prescription option for patients (Tullis, 2021). Of note,
patients with schizophrenia have been excluded from current psychedelic drug trials
because it has been found that these drugs can potentially cause long-lasting psychotic
reactions in patients with a personal or family history of psychosis (Tullis, 2021).
Recently, ketamine, LSD, and other psychedelic drugs have demonstrated the
potential to be a viable treatment option for a variety of mental health disorders (Tullis,
2021). For instance, psychedelic drug treatments have shown to be one of the most
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effective treatment options for PTSD (Tullis, 2021). Other non-psychosis related mental
health disorders have also had positive results from recent smaller clinical trials, which
indicates a strong likelihood for the future use of these alternative drug option (Tullis,
2021). Since these newer trials have been safely administered and have had reliable
results, it is probable that soon there will be a drastic change in treatment options for
mental health disorders.
It is important to note that psychedelic drugs are being studied as a potential
treatment option for non-psychiatric disorders. Psilocybin, otherwise known as
mushrooms, has been studied as a treatment option for end of life care and smoking
cessation (Denis-Lalonde & Estefan, 2020). End of life care is a sensitive topic and can
be difficult for patients to talk about and for providers to treat. In a recent study
conducted with terminally ill patients, psilocybin was shown to have a positive effect on
the palliative care by reducing the anxiety associated with dying (Denis-Lalonde &
Estefan, 2020). Pilot research with psilocybin for smoking cessation has been conducted
and has shown greater success than conventional and pharmaceutical treatment options,
with minimal side effects (Denis-Lalonde & Estefan, 2020). These research trials
demonstrate the expansive capacity that psychedelic and sedative drug treatments may
offer outside of psychiatry.
Psychiatric nurses have the potential to play a crucial role in the implementation
of psychedelic and sedative drug use as a treatment option in practice (Denis-Lalonde &
Estefan, 2020). The literature indicates nurses have played an important role in studies
examining psychedelic drugs, including providing therapy and other forms of support
during clinical trials (Denis-Lalonde & Estefan, 2020). As previously mentioned,
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psychiatric nurses are in a prime role to build a therapeutic and trusting relationship with
patients and are well-aware of the stigmas that may accompany alternative forms of
treatment, such as the ones discussed in this paper. Psychiatric nurses can use the safety
of the therapeutic relationship to examine any concerns patients may have about using
these drugs and can assist the patient with deciding if this is a viable treatment option for
them.
There is a long and difficult path in front of the psychedelic and sedative drug
treatment movement, due to the fact that there are many obstacles, such as stigma, to
overcome; however, this has not deterred scientists from researching the use of these
drugs in current and future practice. Many scientists feel confident that we are on a verge
of a major breakthrough for how we treat mental illness with these alternative forms of
drug treatment, which could lead to significantly improved patient outcomes (Tullis,
2021).
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